Temat: "Quinolones" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Population Pharmacokinetic Modeling and Exposure-Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia.
Autorzy:: Wang X; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.
Raoufinia A; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.
Bihorel S; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.
Passarell J; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.
Mallikaarjun S; Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, Maryland, USA.; Fellow of the American College of Clinical Pharmacology (FCP).
Phillips L; Cognigen Corporation, a SimulationsPlus Company, Buffalo, New York, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2022 Feb; Vol. 11 (2), pp. 150-164. Date of Electronic Publication: 2022 Jan 03.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antipsychotic Agents*
Quinolones*/pharmacokinetics
Schizophrenia*/drug therapy
Aripiprazole ; Female ; Humans ; Piperazines/pharmacokinetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Autorzy:: Elgart A; Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Greenblatt DJ; Tufts University School of Medicine, Boston, Massachusetts, USA.
Loupe PS; Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Zur AA; Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Weiss S; Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Mimrod D; Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Spiegelstein O; Teva Pharmaceutical Industries Ltd, Netanya, Israel.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Nov; Vol. 9 (8), pp. 1015-1024. Date of Electronic Publication: 2020 Apr 01.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cytochrome P-450 CYP3A Inducers/*pharmacology
Cytochrome P-450 CYP3A Inhibitors/*pharmacology
Neuroimmunomodulation/*drug effects
Quinolones/*pharmacokinetics
Adult ; Area Under Curve ; Biological Availability ; Cross-Over Studies ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inducers/administration & dosage ; Cytochrome P-450 CYP3A Inducers/adverse effects ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Interactions ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/statistics & numerical data ; Female ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Quinolones/administration & dosage ; Quinolones/adverse effects ; Quinolones/blood ; Safety

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Quinolone-induced radiation recall dermatitis in breast cancer patient.
Autorzy:: Rafiroiu S; Heritage College of Osteopathic Medicine, Warrensville Heights, Ohio.
Vassil A; Department of Radiation Oncology, Cleveland Clinic, Cleveland, Ohio.
Valente SA; Department of General Surgery, Division of Breast Surgery, Cleveland Clinic, Cleveland, Ohio.; Pokaż więcej
Źródło:: The breast journal [Breast J] 2020 Jul; Vol. 26 (7), pp. 1407-1408. Date of Electronic Publication: 2020 Jan 30.
Typ publikacji:: Journal Article
MeSH Terms:: Breast Neoplasms*/drug therapy
Breast Neoplasms*/radiotherapy
Quinolones*
Radiodermatitis*/chemically induced
Radiodermatitis*/diagnosis
Breast ; Female ; Humans

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: A PIK3CA transgenic mouse model with chemical carcinogen exposure mimics human oral tongue tumorigenesis.
Autorzy:: Tan MT; Department of Bioengineering, Rice University, Houston, TX, USA.
Wu JG; Department of Diagnostic and Biomedical Sciences, University of Texas School of Dentistry, Houston, TX, USA.
Callejas-Valera JL; Cancer Biology Research Center, Sanford Research, Sioux Falls, SD, USA.
Schwarz RA; Department of Bioengineering, Rice University, Houston, TX, USA.
Gillenwater AM; Department of Head and Neck Surgery, M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA.
Richards-Kortum RR; Department of Bioengineering, Rice University, Houston, TX, USA.
Vigneswaran N; Department of Diagnostic and Biomedical Sciences, University of Texas School of Dentistry, Houston, TX, USA.; Pokaż więcej
Źródło:: International journal of experimental pathology [Int J Exp Pathol] 2020 Feb; Vol. 101 (1-2), pp. 45-54. Date of Electronic Publication: 2020 May 21.
Typ publikacji:: Comparative Study; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:: Mutation*
Quinolones*
Cell Transformation, Neoplastic/*chemically induced
Cell Transformation, Neoplastic/*genetics
Class I Phosphatidylinositol 3-Kinases/*genetics
Squamous Cell Carcinoma of Head and Neck/*chemically induced
Squamous Cell Carcinoma of Head and Neck/*genetics
Tongue Neoplasms/*chemically induced
Tongue Neoplasms/*genetics
4-Nitroquinoline-1-oxide ; Animals ; Cell Proliferation ; Cell Transformation, Neoplastic/pathology ; Disease Models, Animal ; Disease Progression ; Lymphocytes/pathology ; Mice, Inbred CBA ; Mice, Transgenic ; Oncogene Proteins, Viral/genetics ; Squamous Cell Carcinoma of Head and Neck/pathology ; Time Factors ; Tongue Neoplasms/pathology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants.
Autorzy:: Feng HP; Merck & Co., Inc., Kenilworth, NJ, USA.
Guo Z; Merck & Co., Inc., Kenilworth, NJ, USA.
Fandozzi C; Merck & Co., Inc., Kenilworth, NJ, USA.
Panebianco D; Merck & Co., Inc., Kenilworth, NJ, USA.
Caro L; Merck & Co., Inc., Kenilworth, NJ, USA.
Wolford D; Merck & Co., Inc., Kenilworth, NJ, USA.
Dreyer DP; Merck & Co., Inc., Kenilworth, NJ, USA.
Valesky R; Merck & Co., Inc., Kenilworth, NJ, USA.
Martinho M; Merck & Co., Inc., Kenilworth, NJ, USA.
Rizk ML; Merck & Co., Inc., Kenilworth, NJ, USA.
Iwamoto M; Merck & Co., Inc., Kenilworth, NJ, USA.
Yeh WW; Merck & Co., Inc., Kenilworth, NJ, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Oct; Vol. 8 (7), pp. 952-961. Date of Electronic Publication: 2019 Jun 07.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Benzofurans/*pharmacokinetics
Cobicistat/*pharmacokinetics
Emtricitabine/*pharmacokinetics
Imidazoles/*pharmacokinetics
Quinolones/*pharmacokinetics
Quinoxalines/*pharmacokinetics
Tenofovir/*pharmacokinetics
Administration, Oral ; Adult ; Area Under Curve ; Benzofurans/administration & dosage ; Cobicistat/administration & dosage ; Drug Administration Schedule ; Drug Combinations ; Drug Interactions ; Emtricitabine/administration & dosage ; Female ; Healthy Volunteers ; Humans ; Imidazoles/administration & dosage ; Male ; Middle Aged ; Quinolones/administration & dosage ; Quinoxalines/administration & dosage ; Tenofovir/administration & dosage

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Pharmacokinetics, Excretion, and Mass Balance of [ C]-Batefenterol Following a Single Microtracer Intravenous Dose (Concomitant to an Inhaled Dose) or Oral Dose of Batefenterol in Healthy Men.
Autorzy:: Ambery C; Clinical Pharmacology Modelling and Simulation, GSK, Stockley Park West, Uxbridge, Middlesex, UK.
Young G; Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Fuller T; GSK, Medicines Research Centre, Stevenage, Hertfordshire, UK.
Lazaar AL; Respiratory Therapy Area Unit, GSK, R&D, King of Prussia, PA, USA.
Pereira A; Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Hughes A; Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Ramsay D; Quanticate Ltd., Edinburgh, UK.
van den Berg F; Hammersmith Medicines Research, London, UK.
Daley-Yates P; Clinical Development, GSK, Research and Development, Uxbridge, Middlesex, UK.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2018 Nov; Vol. 7 (8), pp. 901-910. Date of Electronic Publication: 2018 Sep 19.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carbamates/*administration & dosage
Carbamates/*pharmacokinetics
Quinolones/*administration & dosage
Quinolones/*pharmacokinetics
Administration, Inhalation ; Administration, Intravenous ; Administration, Oral ; Adult ; Biological Availability ; Bronchodilator Agents/administration & dosage ; Bronchodilator Agents/pharmacokinetics ; Bronchodilator Agents/urine ; Carbamates/blood ; Carbamates/urine ; Carbon Radioisotopes/administration & dosage ; Carbon Radioisotopes/blood ; Carbon Radioisotopes/pharmacokinetics ; Carbon Radioisotopes/urine ; Cross-Over Studies ; Feces ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Quinolones/blood ; Quinolones/urine

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Open-Label, Crossover Study to Determine the Pharmacokinetics of Fluticasone Furoate and Batefenterol When Administered Alone, in Combination, or Concurrently.
Autorzy:: Ambery C; Clinical Pharmacology Modelling and Simulation (CPMS), GSK, Stockley Park West, Uxbridge, Middlesex, UK.
Young G; Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Fuller T; GSK, Medicines Research Centre, Stevenage, Hertfordshire, UK.
Georgiou A; Bioanalysis, Immunogenicity and Biomarkers (BIB), GSK, Ware, Hertfordshire, UK.
Ramsay D; Quanticate Ltd, Edinburgh, UK.
Puri A; Hammersmith Medicines Research Ltd, London, UK.
Daley-Yates P; Clinical Development, GSK, Research and Development, Uxbridge, UK.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Feb; Vol. 8 (2), pp. 188-197. Date of Electronic Publication: 2018 Aug 02.
Typ publikacji:: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Androstadienes/*administration & dosage
Carbamates/*administration & dosage
Quinolones/*administration & dosage
Adult ; Androstadienes/adverse effects ; Androstadienes/pharmacokinetics ; Area Under Curve ; Carbamates/adverse effects ; Carbamates/pharmacokinetics ; Cross-Over Studies ; Drug Administration Schedule ; Drug Combinations ; Drug Therapy, Combination ; Female ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Quinolones/adverse effects ; Quinolones/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
Autorzy:: Spiegelstein O; Clinical Pharmacology and Pharmacometrics, Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Mimrod D; Project Leadership, Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Rabinovich L; Clinical Pharmacology and Pharmacometrics, Teva Pharmaceutical Industries Ltd, Frazer, PA, USA.
Eyal E; Global Biostatistics Unit, TEVA Pharmaceutical Industries Ltd, Netanya, Israel.
Sprenger C; Novum, Fargo, ND, USA.
Elgart A; Clinical Pharmacology and Pharmacometrics, Teva Pharmaceutical Industries Ltd, Netanya, Israel.
Samara E; PharmaPolaris International, Davis, CA, USA.
Morganroth J; eResearch Technology, Inc, Philadelphia, PA, USA.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2019 Jan; Vol. 8 (1), pp. 49-59. Date of Electronic Publication: 2018 May 22.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Electrocardiography/*drug effects
Heart/*drug effects
Immunologic Factors/*pharmacology
Quinolones/*pharmacology
Adolescent ; Adult ; Double-Blind Method ; Female ; Heart/physiology ; Heart Rate/drug effects ; Humans ; Huntington Disease/drug therapy ; Immunologic Factors/blood ; Immunologic Factors/pharmacokinetics ; Long QT Syndrome ; Male ; Middle Aged ; Multiple Sclerosis/drug therapy ; Quinolones/blood ; Quinolones/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort.
Autorzy:: Llibre JM; Infectious Diseases and 'Fight AIDS' Foundation, University Hospital Germans Trias i Pujol, Badalona, Spain.
Montoliu A; Statistics and Epidemiology, Centre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT, CIBERESP), Badalona, Spain.
Miró JM; Hospital Clínic- IDIBAPS, University of Barcelona, Barcelona, Spain.
Domingo P; Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Riera M; Hospital Son Espases, Palma de Mallorca, Spain.
Tiraboschi J; Infectious Diseases, Hospital Universitari de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Curran A; Infectious Diseases, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Homar F; Hospital Son Llàtzer, Palma de Mallorca, Spain.
Ambrosioni J; Hospital Clínic- IDIBAPS, University of Barcelona, Barcelona, Spain.
Abdulghani N; Hospital de Santa Maria, Lleida, Spain.
Force L; Internal Medicine, Hospital de Mataró-Consorci Sanitari del Maresme, Mataró, Spain.
Peraire J; Internal Medicine, Hospital Joan XXIII, Tarragona, Spain.
Casabona J; Statistics and Epidemiology, Centre d'Estudis Epidemiològics sobre les ITS i la Sida de Catalunya (CEEISCAT, CIBERESP), Badalona, Spain.; Pokaż więcej
Corporate Authors:: PISCIS Cohort group
Źródło:: HIV medicine [HIV Med] 2019 Mar; Vol. 20 (3), pp. 237-247. Date of Electronic Publication: 2019 Jan 27.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Cobicistat/*adverse effects
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*adverse effects
Quinolones/*adverse effects
Raltegravir Potassium/*adverse effects
Adult ; CD4 Lymphocyte Count ; Cobicistat/administration & dosage ; Female ; HIV Infections/immunology ; Heterocyclic Compounds, 3-Ring/administration & dosage ; Humans ; Male ; Middle Aged ; Oxazines ; Piperazines ; Proportional Hazards Models ; Prospective Studies ; Pyridones ; Quinolones/administration & dosage ; Raltegravir Potassium/administration & dosage ; Spain

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Autorzy:: Baldin G; Institute of Clinical Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Ciccullo A; Institute of Clinical Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Capetti A; Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy.
Rusconi S; Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy.
Sterrantino G; Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy.
Cossu MV; Division of Infectious Diseases, Department of Infectious Diseases, Luigi Sacco University Hospital, Milan, Italy.
Giacomelli A; Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy.
Lagi F; Division of Tropical and Infectious Diseases, 'Careggi' Hospital, Florence, Italy.
Latini A; Infectious Dermatology and Allergology Unit, IFO S. Gallicano Institute (IRCCS), Rome, Italy.
Bagella P; Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.
De Luca A; University Division of Infectious Diseases, Siena University Hospital, Siena, Italy.
Di Giambenedetto S; Institute of Clinical Infectious Diseases, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Madeddu G; Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.; Pokaż więcej
Źródło:: HIV medicine [HIV Med] 2019 Feb; Vol. 20 (2), pp. 164-168. Date of Electronic Publication: 2018 Nov 20.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study; Observational Study
MeSH Terms:: Cobicistat/*therapeutic use
Emtricitabine/*therapeutic use
HIV Infections/*drug therapy
Heterocyclic Compounds, 3-Ring/*therapeutic use
Quinolones/*therapeutic use
Tenofovir/*therapeutic use
Adult ; Cobicistat/adverse effects ; Drug Therapy, Combination/adverse effects ; Emtricitabine/adverse effects ; Female ; HIV Infections/virology ; HIV-1/genetics ; Heterocyclic Compounds, 3-Ring/adverse effects ; Humans ; Male ; Middle Aged ; Oxazines ; Piperazines ; Pyridones ; Quinolones/adverse effects ; RNA, Viral/genetics ; Retrospective Studies ; Tenofovir/adverse effects ; Viral Load

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Towards functional selectivity for α6β3γ2 GABA A receptors: a series of novel pyrazoloquinolinones.
Autorzy:: Treven M; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Siebert DCB; Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
Holzinger R; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Bampali K; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Fabjan J; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Varagic Z; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Wimmer L; Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
Steudle F; Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Scholze P; Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University Vienna, Vienna, Austria.
Schnürch M; Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
Mihovilovic MD; Institute of Applied Synthetic Chemistry, TU Wien, Vienna, Austria.
Ernst M; Department of Molecular Neurosciences, Center for Brain Research, Medical University Vienna, Vienna, Austria.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2018 Feb; Vol. 175 (3), pp. 419-428. Date of Electronic Publication: 2017 Dec 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: GABA Modulators/*pharmacology
Pyrazoles/*pharmacology
Quinolones/*pharmacology
Receptors, GABA-A/*physiology
Animals ; Dose-Response Relationship, Drug ; Female ; GABA Modulators/chemistry ; Pyrazoles/chemistry ; Quinolones/chemistry ; Rats ; Rats, Sprague-Dawley ; Xenopus laevis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.
Autorzy:: Langron E; Research Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.
Simone MI; Discipline of Chemistry, School of Environmental and Life Sciences, Priority Research Centre for Chemical Biology and Clinical Pharmacology, The University of Newcastle, Callaghan, NSW, Australia.
Delalande CM; Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
Reymond JL; Department of Chemistry and Biochemistry, University of Bern, Bern, Switzerland.
Selwood DL; Wolfson Institute for Biomedical Research, University College London, London, UK.
Vergani P; Research Department of Neuroscience, Physiology and Pharmacology, University College London, London, UK.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2017 Apr; Vol. 174 (7), pp. 525-539. Date of Electronic Publication: 2017 Feb 14.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Fluorescence*
Aminophenols/*analysis
Aminophenols/*pharmacology
Bacterial Proteins/*analysis
Cystic Fibrosis Transmembrane Conductance Regulator/*metabolism
Drug Evaluation, Preclinical/*methods
Luminescent Proteins/*analysis
Quinolones/*analysis
Quinolones/*pharmacology
Small Molecule Libraries/*analysis
Small Molecule Libraries/*pharmacology
Aminophenols/chemical synthesis ; Aminophenols/chemistry ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; Cystic Fibrosis Transmembrane Conductance Regulator/genetics ; HEK293 Cells ; Humans ; Luminescent Proteins/genetics ; Luminescent Proteins/metabolism ; Molecular Structure ; Quinolones/chemical synthesis ; Quinolones/chemistry ; Small Molecule Libraries/chemical synthesis ; Small Molecule Libraries/chemistry

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.
Autorzy:: Vaidya SS; Drug Metabolism and Pharmacokinetics, Clinical Pharmacokinetics/Pharmacodynamics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Khindri S; Translational Medicine, Novartis Institutes for BioMedical Research, Horsham, West Sussex, UK.
Maahs S; Translational Medicine, Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
Machineni S; Integrated Information and Sciences, Novartis Healthcare Pvt Ltd, Hyderabad, India.
Hara H; Drug Metabolism and Pharmacokinetics, Advanced BA & Automation, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Juan A; Seaview Research, Inc, Miami, FL, USA.
Kaiser G; Drug Metabolism and Pharmacokinetics, Clinical Pharmacokinetics/Pharmacodynamics, Novartis Institutes for BioMedical Research, Basel, Switzerland.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2016 Jul; Vol. 5 (4), pp. 285-95. Date of Electronic Publication: 2016 Jan 22.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*administration & dosage
Anti-Inflammatory Agents/*administration & dosage
Indans/*administration & dosage
Lung/*metabolism
Pregnadienediols/*administration & dosage
Quinolones/*administration & dosage
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Adrenergic beta-2 Receptor Agonists/pharmacokinetics ; Adult ; Anti-Inflammatory Agents/adverse effects ; Anti-Inflammatory Agents/pharmacokinetics ; Area Under Curve ; Biological Availability ; Charcoal/chemistry ; Cross-Over Studies ; Drug Combinations ; Drug Delivery Systems ; Female ; Humans ; Indans/adverse effects ; Indans/pharmacokinetics ; Male ; Nebulizers and Vaporizers ; Pregnadienediols/adverse effects ; Pregnadienediols/pharmacokinetics ; Quinolones/adverse effects ; Quinolones/pharmacokinetics ; Tissue Distribution ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Open-Label, Randomized, 6-Way Crossover, Single-Dose Study to Determine the Pharmacokinetics of Batefenterol (GSK961081) and Fluticasone Furoate When Administered Alone or in Combination.
Autorzy:: Ambery C; Quantitative Sciences Division, GSK, Stockley Park West, Uxbridge, Middlesex, UK. .
Riddell K; GSK, Ermington, NSW, Australia.
Daley-Yates P; Clinical Pharmacology, GSK, Research and Development, Uxbridge, Middlesex, UK.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2016 Sep; Vol. 5 (5), pp. 399-407. Date of Electronic Publication: 2016 Jun 26.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:: Androstadienes/*administration & dosage
Bronchodilator Agents/*administration & dosage
Carbamates/*administration & dosage
Quinolones/*administration & dosage
Administration, Inhalation ; Adolescent ; Adult ; Androstadienes/pharmacokinetics ; Area Under Curve ; Bronchodilator Agents/pharmacokinetics ; Carbamates/pharmacokinetics ; Cross-Over Studies ; Drug Combinations ; Dry Powder Inhalers ; Female ; Humans ; Male ; Middle Aged ; Quinolones/pharmacokinetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Pharmacokinetic and bioequivalence evaluation of single-tablet and separate-tablet regimens for once-daily cobicistat-boosted elvitegravir in healthy Japanese male subjects: A randomized, two-way crossover study.
Autorzy:: Shiomi M; Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.
Matsuki S; Medical Co. LTA Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan.
Ikeda A; Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.
Ishikawa T; Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.
Nishino N; Clinical Development Department, Pharmaceutical Division, Japan Tobacco Inc., Tokyo, Japan.
Kimura M; Medical Co. LTA Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan.
Kumagai Y; Clinical Research Center, Kitasato University, Kanagawa, Japan.
Irie S; Medical Co. LTA Kyushu Clinical Pharmacology Research Clinic, Fukuoka, Japan.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2015 May-Jun; Vol. 4 (3), pp. 218-25. Date of Electronic Publication: 2014 Oct 27.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial
MeSH Terms:: Anti-HIV Agents/*administration & dosage
Anti-HIV Agents/*pharmacokinetics
Cobicistat/*administration & dosage
Cobicistat/*pharmacokinetics
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/*administration & dosage
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/*pharmacokinetics
Quinolones/*administration & dosage
Quinolones/*pharmacokinetics
Administration, Oral ; Adult ; Anti-HIV Agents/adverse effects ; Area Under Curve ; Cobicistat/adverse effects ; Cross-Over Studies ; Drug Administration Schedule ; Drug Therapy, Combination ; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination/adverse effects ; Healthy Volunteers ; Humans ; Japan ; Least-Squares Analysis ; Male ; Metabolic Clearance Rate ; Middle Aged ; Models, Biological ; Quinolones/adverse effects ; Tablets ; Therapeutic Equivalency ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.
Autorzy:: Rinaldi B; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.; Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy.
Donniacuo M; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.
Sodano L; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.
Gritti G; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.
Martuscelli E; Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Orlandi A; Anatomic Pathology, Department of Biomedicine and Prevention, University of Rome 'Tor Vergata', Rome, Italy.
Rafaniello C; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.; Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy.
Rossi F; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.; Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy.
Calzetta L; Department of Systems Medicine, University of Rome 'Tor Vergata', Rome, Italy.
Capuano A; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.; Regional Centre for Pharmacovigilance and Pharmacoepidemiology, Department of Experimental Medicine, Section of Pharmacology L. Donatelli, Second University of Naples, Naples, Italy.
Matera MG; Centre of Excellence for Cardiovascular Diseases, Second University of Naples, Naples, Italy.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2015 Jul; Vol. 172 (14), pp. 3627-37. Date of Electronic Publication: 2015 May 12.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adrenergic beta-1 Receptor Antagonists/*pharmacology
Adrenergic beta-2 Receptor Agonists/*pharmacology
Heart Failure/*drug therapy
Indans/*pharmacology
Metoprolol/*pharmacology
Myocardial Infarction/*drug therapy
Quinolones/*pharmacology
Receptors, Adrenergic, beta/*metabolism
Ventricular Remodeling/*drug effects
Adrenergic beta-1 Receptor Antagonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Animals ; Blood Pressure/drug effects ; Disease Models, Animal ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Heart Failure/physiopathology ; Heart Rate/drug effects ; Indans/administration & dosage ; Male ; Metoprolol/administration & dosage ; Myocardial Infarction/physiopathology ; Quinolones/administration & dosage ; Rats ; Rats, Wistar

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Synthesis and SAR studies of novel 6,7,8-substituted 4-substituted benzyloxyquinolin-2(1H)-one derivatives for anticancer activity.
Autorzy:: Chen YF; The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia Sinica, Taichung, Taiwan; School of Pharmacy, China Medical University, Taichung, Taiwan.
Lin YC
Morris-Natschke SL
Wei CF
Shen TC
Lin HY
Hsu MH
Chou LC
Zhao Y
Kuo SC
Lee KH
Huang LJ; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2015 Mar; Vol. 172 (5), pp. 1195-221. Date of Electronic Publication: 2015 Jan 13.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*pharmacology
Quinolones/*pharmacology
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Structure ; Quinolones/chemical synthesis ; Quinolones/chemistry ; Structure-Activity Relationship

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Pharmacokinetics and pharmacodynamics of GSK961081, a novel inhaled muscarinic antagonist β2 -agonist, and fluticasone propionate administered alone, concurrently and as a combination blend formulation in healthy volunteers.
Autorzy:: Norris V; GlaxoSmithKline, UK.
Ambery C; GlaxoSmithKline, UK.
Riley T; GlaxoSmithKline, UK.; Pokaż więcej
Źródło:: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2014 Jul; Vol. 3 (4), pp. 305-13. Date of Electronic Publication: 2014 Feb 20.
Typ publikacji:: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Adrenergic beta-2 Receptor Agonists/*pharmacokinetics
Carbamates/*pharmacokinetics
Fluticasone/*pharmacokinetics
Muscarinic Antagonists/*pharmacokinetics
Quinolones/*pharmacokinetics
Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists/administration & dosage ; Adrenergic beta-2 Receptor Agonists/adverse effects ; Area Under Curve ; Biomarkers/blood ; Carbamates/administration & dosage ; Carbamates/adverse effects ; Cross-Over Studies ; Double-Blind Method ; Drug Combinations ; Drug Compounding ; Drug Therapy, Combination ; Dry Powder Inhalers ; Female ; Fluticasone/administration & dosage ; Fluticasone/adverse effects ; Healthy Volunteers ; Humans ; Hydrocortisone/blood ; Male ; Muscarinic Antagonists/administration & dosage ; Muscarinic Antagonists/adverse effects ; Quinolones/administration & dosage ; Quinolones/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Autorzy:: Aouri M; Innovation & Development Laboratory, Service of Biomedicine, Centre Hospitalier Universitaire Vaudois, Switzerland.
Calmy A
Hirschel B
Telenti A
Buclin T
Cavassini M
Rauch A
Decosterd LA; Pokaż więcej
Źródło:: Journal of mass spectrometry : JMS [J Mass Spectrom] 2013 May; Vol. 48 (5), pp. 616-25.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Anti-Retroviral Agents/*blood
Chromatography, Liquid/*methods
HIV Infections/*blood
HIV Infections/*drug therapy
Nitriles/*blood
Pyrimidines/*blood
Quinolones/*blood
Tandem Mass Spectrometry/*methods
Anti-Retroviral Agents/chemistry ; Anti-Retroviral Agents/therapeutic use ; Drug Stability ; Humans ; Nitriles/chemistry ; Nitriles/therapeutic use ; Pyrimidines/chemistry ; Pyrimidines/therapeutic use ; Quinolones/chemistry ; Quinolones/therapeutic use ; Reproducibility of Results ; Rilpivirine ; Sensitivity and Specificity

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: FOXO1 inhibition prevents renal ischemia-reperfusion injury via cAMP-response element binding protein/PPAR-γ coactivator-1α-mediated mitochondrial biogenesis.
Autorzy:: Wang D; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
Wang Y; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.; Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zou X; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Shi Y; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
Liu Q; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
Huyan T; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
Su J; Department of Pathology, School of Basic Medical Sciences, Peking University, Beijing, China.
Wang Q; Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China.
Zhang F; Research Center of Integrative Medicine, School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, China.
Li X; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.
Tie L; State Key Laboratory of Natural and Biomimetic Drugs, Department of Pharmacology, School of Basic Medical Sciences, Peking University and Beijing Key Laboratory of Tumor Systems Biology, Peking University, Beijing, China.; Pokaż więcej
Źródło:: British journal of pharmacology [Br J Pharmacol] 2020 Jan; Vol. 177 (2), pp. 432-448. Date of Electronic Publication: 2019 Dec 23.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Organelle Biogenesis*
Cyclic AMP Response Element-Binding Protein/*metabolism
Forkhead Box Protein O1/*antagonists & inhibitors
Kidney Diseases/*prevention & control
Kidney Tubules/*drug effects
Mitochondria/*drug effects
Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/*metabolism
Quinolones/*pharmacology
Reperfusion Injury/*prevention & control
Animals ; Apoptosis/drug effects ; Cell Line ; Disease Models, Animal ; Forkhead Box Protein O1/metabolism ; Humans ; Kidney Diseases/metabolism ; Kidney Diseases/pathology ; Kidney Tubules/metabolism ; Kidney Tubules/pathology ; Male ; Mice, Inbred C57BL ; Mitochondria/metabolism ; Mitochondria/pathology ; Mitophagy/drug effects ; Reperfusion Injury/metabolism ; Reperfusion Injury/pathology ; Signal Transduction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Quinolones"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Publikacja

Język